BCR-ABL1 Fusion Protein Expression: Clinical Trials

3 trials for BCR-ABL1 Fusion Protein Expression, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 unknown. 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Recruiting 1
Phase 31Unknown 1

Follow BCR-ABL1 Fusion Protein Expression: new trials by email Literature Review of BCR-ABL1 Fusion Protein Expression trials Research Report on BCR-ABL1 Fusion Protein Expression

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
Flumatinib - Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression
Phase 3UnknownZhongda Hospital282020-03-012022-03-24
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
Blinatumomab, Cytarabine, Methotrexate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Phase 2RecruitingM.D. Anderson Cancer Center902017-11-292026-05-20
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
Cyclophosphamide, Cytarabine, Dasatinib - Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression
Phase 2CompletedM.D. Anderson Cancer Center1072006-09-282025-02-17

Narrower conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Blast Crisis (2)  ·  Leukemia, Myeloid, Accelerated Phase (1)  ·  Neoplasm, Residual (1)

Broader conditions

Hematologic Diseases (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Leukemia (3)  ·  Leukemia, Lymphoid (3)  ·  Lymphatic Diseases (3)  ·  Lymphoproliferative Disorders (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Neoplastic Processes (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Bone Marrow Diseases (2)  ·  Carcinogenesis (2)

Interventions

Cytarabine (2)  ·  Methotrexate (2)  ·  merphos (2)  ·  Calcium Dobesilate (1)  ·  Cyclophosphamide (1)  ·  Dasatinib (1)  ·  Dexamethasone (1)  ·  Doxorubicin (1)  ·  N,N-dicyclohexyl-isoborneol-10-sulfonamide (1)  ·  Prednisone (1)  ·  Vincristine (1)  ·  auricularum (1)  ·  blinatumomab (1)  ·  deltacortene (1)  ·  dexamethasone 21-phosphate (1)

Sponsors

M.D. Anderson Cancer Center (2)  ·  Zhongda Hospital (1)

Countries

United States (2)  ·  China (1)

Top investigators

Elias Jabbour (1)  ·  Farhad Ravandi-Kashani, MD (1)  ·  Zheng Ge, PhD. MD. (1)

Results publications

PMID 20466853, PMID 36402146, PMID 39028925, PMID 40369607